MedPath
Found 33 clinical trials|View Analysis
Sort by:

Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

Phase 1
Recruiting
Conditions
Hepatocellular Carcinoma
HCC
Interventions
First Posted Date
2024-07-30
Last Posted Date
2024-07-30
Lead Sponsor
Assiut University
Target Recruit Count
150
Registration Number
NCT06527495
Locations
🇪🇬

NLI, Shibīn Al Kawm, Menoufia, Egypt

Pharmacogenetic Study of Bisoprolol in Egyptian Patients With Acute Coronary Syndrome

Phase 2
Completed
Conditions
Acute Coronary Syndrome
Interventions
First Posted Date
2022-09-10
Last Posted Date
2023-06-07
Lead Sponsor
Damanhour University
Target Recruit Count
127
Registration Number
NCT05536271
Locations
🇪🇬

Damanhour University, Damanhūr, Behira, Egypt

Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

Completed
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2022-03-22
Last Posted Date
2023-07-28
Lead Sponsor
Rehab Werida
Target Recruit Count
107
Registration Number
NCT05291338
Locations
🇪🇬

Ain Shams University hepatoma group, EL Demerdash Hospital, Cairo, Egypt., Cairo, Egypt

Determining the Pharmacogenetic Basis of Non-responsiveness to the Sedative Effects of Dexmedetomidine in Children

Conditions
Procedural Anxiety
Dexmedetomidine
Pharmacogenetic Study
Interventions
First Posted Date
2020-07-15
Last Posted Date
2022-03-16
Lead Sponsor
Hong Kong Children's Hospital
Target Recruit Count
100
Registration Number
NCT04471402
Locations
🇭🇰

Hong Kong Children's Hospital, Hong Kong, Hong Kong

Naproxen Pharmacogenetic Study (Project 1, Aim 2)

Phase 4
Conditions
Pharmacogenetics
Interventions
First Posted Date
2020-06-26
Last Posted Date
2020-06-29
Lead Sponsor
University of Washington
Target Recruit Count
30
Registration Number
NCT04449471
Locations
🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL

Not Applicable
Conditions
Hepatic Veno-Occlusive Disease
Nephroblastoma
Acute Lymphoblastic Leukemia
Interventions
Other: Blood test for genetic analysis
First Posted Date
2019-11-19
Last Posted Date
2019-11-19
Lead Sponsor
University Hospital, Angers
Target Recruit Count
150
Registration Number
NCT04168788
Locations
🇫🇷

University Hospital of Bordeaux, Bordeaux, France

🇫🇷

Centre Oscar Lambret, Lille, France

🇫🇷

University Hospital of Nantes, Nantes, France

and more 13 locations

NeoFent-I Study; Fentanyl Treatment in Newborn Infants; a Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study

Phase 4
Completed
Conditions
Pain
Interventions
First Posted Date
2019-04-01
Last Posted Date
2019-04-01
Lead Sponsor
Lund University
Target Recruit Count
32
Registration Number
NCT03897452
Locations
🇸🇪

Neonatal Intensive Care Unit, Skåne University Hospital, Lund, Sweden

A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers

Phase 2
Completed
Conditions
Alcohol Use Disorder (AUD)
Alcoholism
Interventions
Behavioral: Medical Management
Drug: Topiramate
Drug: Inactive Placebo
First Posted Date
2015-02-26
Last Posted Date
2022-01-20
Lead Sponsor
University of Pennsylvania
Target Recruit Count
320
Registration Number
NCT02371889
Locations
🇺🇸

Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States

🇺🇸

University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States

Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder

Phase 2
Completed
Conditions
Alcohol Use Disorder
Interventions
Drug: Placebo
Drug: Ondansetron
First Posted Date
2015-02-03
Last Posted Date
2022-01-14
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
293
Registration Number
NCT02354703
Locations
🇺🇸

University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States

🇺🇸

MPRC, Baltimore, Maryland, United States

🇺🇸

Philadelphia VAMC, Philadelphia, Pennsylvania, United States

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Phase 4
Recruiting
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2015-01-27
Last Posted Date
2024-08-01
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
162
Registration Number
NCT02347111
Locations
🇺🇸

Jesse Brown VA Medical Center, Chicago, Illinois, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath